Brian Nichols is the co-founder of Angel Squad, a community where you’ll learn how to angel invest and get a chance to invest as little as $1k into Hustle Fund's top performing early-stage startups

ElevenLabs hit roughly $500 million in ARR by April 2026, up from about $120 million two years earlier, and added $100 million of that in a single quarter. For a company founded in 2022, that is one of the steeper revenue curves in AI. It is also why ElevenLabs keeps surfacing on secondary platforms, and why accredited investors keep asking whether the entry price still makes sense.

Here is the setup that makes ElevenLabs different from the average secondary. Unlike a lot of private names where sellers are lining up, demand for ElevenLabs shares is currently running ahead of supply. The stock trades just below the price of a recent up-round that roughly tripled the valuation. That is a hot-name dynamic, and hot names are exactly where buyers overpay for narrative if they are not careful.

This guide is for the accredited investor sizing up private-market exposure, not the retail buyer waiting for a ticker. We will walk through how the shares work, what the numbers actually say, and which terms decide whether you make money.

What ElevenLabs Pre-IPO Shares Are (and What They Are Not)

Pre-IPO shares in ElevenLabs are almost always existing shares being sold by an employee, a founder, or an early investor in a secondary transaction. They are not publicly traded stock. They do not come with continuous pricing, broad SEC reporting, or guaranteed liquidity.

The primary-versus-secondary distinction matters. A primary round creates new shares and puts cash on ElevenLabs' balance sheet, which is what the Series D did. A secondary sale just transfers ownership between two private parties and funds nothing inside the company. Secondaries usually reflect a seller's liquidity needs, their bargaining position, and whatever information gap exists between them and you.

So treat a private listing as a negotiated transaction, not a quote. There is no ElevenLabs ticker and no live market, just a specific block of shares with specific rights and transfer terms. Your job is to figure out exactly what those are.

What Is the Current Valuation of ElevenLabs?

ElevenLabs' last primary valuation is $11 billion, set in its Series D in early 2026. The round was led by Sequoia Capital, with Sequoia's Andrew Reed joining the board, and it more than tripled the company's $3.3 billion valuation from a year earlier. A later close brought in a long list of institutional and strategic names, including BlackRock, Wellington, D.E. Shaw, Schroders, NVIDIA, Salesforce, and Deutsche Telekom. Earlier, in late 2025, ElevenLabs ran a roughly $100 million staff tender offer at a $6.6 billion valuation, so the path from $3.3 billion to $11 billion ran through a real interim mark, not a single leap.

ElevenLabs, founded in 2022 and led by CEO Mati Staniszewski, builds AI models for generating and editing speech. The core product turns text into remarkably human-like audio and can clone a voice from about a minute of sample, sold through a web studio and a developer API. The flagship Eleven v3 model supports 70-plus languages with controllable emotional delivery, and the platform has expanded into dubbing, a voice marketplace, conversational AI agents, and a licensed-data music product.

How Does ElevenLabs Generate Revenue?

ElevenLabs runs a subscription SaaS model with usage-based pricing tied to the volume of speech processed, from a free tier up to custom enterprise contracts, with creator plans starting around $22 a month. The customer base has scaled to roughly a 50/50 split between self-serve and enterprise.

The growth engine has shifted toward enterprise. ElevenLabs reports that 41% of Fortune 500 companies use the platform, and its voice-agent business is where the net-new revenue is coming from. Revolut deployed ElevenLabs agents across UK and European support covering more than 4 million customers, and Klarna put a voice agent in front of 35 million US customers as first-line phone support. Deutsche Telekom is rolling it out as a network-integrated call assistant, and a Spotify partnership aims to make ElevenLabs the default generation layer for AI-produced audiobooks. On top of that sits a music product trained on licensed data, which is a deliberate contrast to competitors facing copyright suits.

Why Are Investors Bullish on ElevenLabs?

Start with the trajectory. ARR went from roughly $25 million in 2023 to about $120 million in 2024, then $330 million by the end of 2025, and crossed $500 million in April 2026. Adding $100 million of net-new ARR in a single quarter, mostly from enterprise voice agents, is the kind of number that gets a Series D oversubscribed.

The strategic story is specialization. Most of ElevenLabs' largest competitors, the big AI labs and platforms, treat audio as a side feature. ElevenLabs treats it as the entire company, with a research team focused only on audio quality, and that focus shows up in benchmarks and in enterprise win rates. Its voice marketplace, where creators monetize their own voices, layers network effects on top of the model.

Our very own Hustle Fund GP, Elizabeth Yin, has made the point that in hype markets, differentiation is the whole game. As she puts it, a startup needs to be 10x different and 10x better than every alternative, not just its direct competitors. ElevenLabs' bet is that owning audio-specialist quality is that 10x edge against generalist platforms. If that holds, it is a real moat. The open question is whether quality alone stays defensible as bigger players pour resources into the category.

What Are the Biggest Risks for ElevenLabs Investors?

Three company-level risks deserve attention.

Regulatory and ethical backlash. Voice cloning has already been used for deepfakes and scams, and the technology has drawn scrutiny from US legislators, including Senate inquiries into ElevenLabs' scam-prevention controls. Tightening rules on synthetic voice could constrain product capabilities or pile on compliance costs.

Competition and the quality-cost squeeze. OpenAI, Google, Meta, and Microsoft all have audio capabilities, and a specialized stack of players like Cartesia in text-to-speech and Deepgram in speech-to-text competes at the component level. ElevenLabs' edge is quality bought through heavy research and compute. Over time it may face pressure to trade some of that quality for lower cost, which would erode the very thing that differentiates it from better-funded rivals.

Talent and ecosystem friction. The voice marketplace can alienate professional voice actors and unions, echoing the SAG-AFTRA fights over AI. Paying creators in platform credits rather than cash may not be enough to keep that ecosystem onside.

The Risks Investors Underprice: Liquidity, Dilution, and Information Asymmetry

Company risk gets the headlines. Structural private-market risk is what actually shows up in your returns.

Liquidity risk is the one buyers consistently underprice. ElevenLabs has said it is targeting IPO readiness within two to three years, with no underwriters disclosed, so plan for a multi-year hold and the chance that interim liquidity comes through tender windows rather than a listing.

Dilution is not hypothetical. Option pool refreshes, future rounds, and convertibles can shrink your ownership even if you never sell a share, and AI companies competing for research talent run large pools. Before assuming your stake is safe, read up on pro rata rights and anti-dilution provisions, most of which secondary buyers of common do not get.

Information asymmetry is the structural edge every seller has. ElevenLabs does not file public quarterlies. You are often buying common stock from someone who can see more than you can, and that gap is the entire reason the trade exists.

This is also where ElevenLabs' price signal cuts the opposite way from a discount name. Elizabeth Yin likes to say that valuation is never really about what a company is "worth." It is about supply and demand, the supply of a given block of shares and the demand from investors at that moment. With ElevenLabs, buy interest is outstripping supply, which means the pressure runs toward paying up. That dynamic does not make the company a better business. It just means you are more likely to be the one reaching on price, so discipline matters more, not less.

What the Numbers Actually Say

Here is the math, stripped of narrative.

The headline trap, first. If you pull ElevenLabs up on a secondary platform, you may see a summary screen that marks the company near a $1 billion "valuation" and even labels the last round a steep down round. Ignore that figure. It is an artifact of how the platform applies share-count math to a single sub-class of shares, and it marks off a sliver of the cap table rather than the roughly 600 million fully diluted shares. The real round priced at about $54.18 per share for an $11 billion valuation. The tell is in the per-share progression: the Series C priced near $17.47 and the Series D near $54.18, which is a 3x step-up, not a markdown. This is the whole reason you read the per-share terms and the share count instead of trusting a headline number on a screen.

Entry price versus last round. The Series D priced around $54.18 per share. On the secondary market, ElevenLabs has recently traded near $52, roughly a 3% discount to that round price, with demand currently running ahead of supply. After a quiet stretch in 2025, the stock re-rated sharply higher in early 2026 alongside the new round.

Trailing and forward multiples. At $11 billion against roughly $330 million of ARR at the end of 2025, ElevenLabs priced at about 33x revenue. Against the $500 million ARR run-rate by April 2026, that compresses to roughly 22x. Rich, but the valuation is growing into itself as ARR climbs, the same pattern you see across the fastest private AI names.

Peer comparison. That premium is steep next to public comps. Mature public infrastructure and developer-software names tend to trade in the high-single to mid-teens forward revenue range even while growing well. ElevenLabs at low-20s forward carries a clear private-AI premium: faster growth, a smaller base, and no public-market discipline yet. Whether that premium is fair depends on durability of growth and margins, which loops back to the quality-cost question. For a refresher on how multiples actually map to returns, our explainer on drag-along rights covers some of the control dynamics that come with a preferred-heavy stack like this one.

Revenue trajectory. Roughly $25 million in 2023, about $120 million in 2024, around $330 million by the end of 2025, and a $500 million run-rate by April 2026. Worth noting: revenue per employee has actually declined as headcount scaled, which is normal during an aggressive hiring and international expansion phase but worth watching.

Profitability. ElevenLabs has not disclosed margins or EBITDA. The model is compute-intensive, the research team is expensive by design, and the company is opening offices across a dozen-plus cities. The investment case rests on continued growth and a durable quality edge, not on a visible earnings floor.

The Diligence That Actually Matters: Terms Every Buyer Should Understand

The industry myth is that a price below the last round means you are getting a deal. Often that gap reflects share class, preference stacking, or transfer restrictions that change what you actually own. The real diligence is the cap table position and the legal structure of what is transferred, not the headline number. Our plain-English guide to investment terms covers the vocabulary if any of this is new.

The terms that decide your outcome:

• Share class. Common or preferred. Most secondary blocks are common, and that drives outcomes more than the valuation does.
• Liquidation preference and preferred rights. ElevenLabs' preferred carries a 1x non-participating preference with broad-based anti-dilution, which is a relatively clean stack. But it also carries an 8% non-cumulative dividend and redemption rights at the preferred level, protections that common holders do not get. If you are buying common, understand what sits above you. Our breakdown of liquidation preference is worth reading before you sign.
• Fully diluted ownership. Your percentage assuming all options, warrants, and convertibles convert. With a roughly 600 million fully diluted share base, the difference between a per-class count and the real denominator is exactly what trips up the headline valuation above.
• 409A valuation. A tax-purpose mark that sits below a negotiated secondary price because the two solve different problems. Don't anchor on it.
• Information rights. Whether you get financials after you buy. Common holders often get none, which means you are holding something you cannot monitor.
• ROFR and transfer restrictions. ElevenLabs allows direct transfers only under certain conditions, and the company can match or block your deal even after you sign. A signed purchase agreement is not ownership.
• Lockup. Post-IPO selling restrictions, often 180 days. Your liquidity event is the lockup expiration, not the listing.

If a seller or platform cannot explain these clearly for the exact shares on offer, that opacity is itself the risk signal.

Deal Mechanics: Direct Secondary, SPVs, Forward Purchases, and the Fee Stack

How you get exposure matters as much as the price.

A direct secondary gives you ownership of the actual transferred shares, subject to ElevenLabs' approval and transfer terms. An SPV gives you exposure through a pooled vehicle, which simplifies admin but adds a fee layer and reduces your visibility into the underlying shares. If you are new to these, our explainer on special purpose vehicles is worth a read first.

Two structures deserve specific caution, and they matter more in a hot name where access is scarce.

Forward purchase contracts. Some "pre-IPO ElevenLabs" offers are not a transfer of shares at all. They are a contract giving you synthetic exposure to a seller's shares, with the actual transfer happening only at a future IPO or liquidity event. You do not hold shares in the meantime, and if the seller defaults or cannot deliver at settlement, you are exposed to counterparty risk, not just market risk. Confirm whether you are buying shares or a promise about shares.

Second- and third-layer SPVs. In a supply-constrained name like this, access often arrives through an SPV that itself buys into another SPV. Each layer stacks its own management fee and carry, and each layer puts more distance between you and the cap table. By the time you are two or three vehicles deep, you may be paying meaningful fees for exposure you cannot fully see. Ask how many layers sit between your check and ElevenLabs' shares.

On top of all that, your all-in cost is rarely just the share price. Spread, platform fees, broker-dealer commission, legal review, and SPV overhead can turn a decent entry into a mediocre one before the company changes in value at all. An indication of interest is not an allocation, and deals fail for boring reasons: unclean title, blocked transfers, terms shifting after the handshake. Don't anchor until cash and shares settle.

Eligibility and Compliance

Most direct private-market offerings are limited to accredited investors based on income, net worth, or credentials. Qualified purchaser status matters when a deal is packaged through a pooled fund. Regulation D frames the offering: 506(b) relies on pre-existing relationships, while 506(c) permits broader marketing but requires verified accredited status. KYC, AML, source-of-funds review, broker-dealer involvement, and escrow are protective infrastructure, not paperwork friction.

Where Accredited Investors May Access ElevenLabs Shares

Access usually comes through a few channels, each with different mechanics and information rights. Secondary platforms such as Notice, Forge Global, Hiive, and EquityZen list growth-stage names and let you compare quotes, though share class and transfer terms vary by listing. Pre-IPO and venture funds hold positions across private companies and give diversification at the cost of control over any single name. Public proxies offer indirect, diluted exposure through ElevenLabs' larger investors. And angel investing communities sometimes surface curated SPV access to growth-stage deals for members who have built the right relationships.

How This Differs From Early-Stage Venture Access

Late-stage secondaries behave differently from early-stage venture. The literacy you build evaluating seed founders, reading cap tables, sizing positions, asking sharp questions, transfers directly. But an $11 billion secondary is a different animal. You are underwriting price, share class, and liquidity rather than a founder bet. Investors who only ever look at one stage tend to be worse at both.

Liquidity, Lockups, and Exit Paths

Private shares can exit through an acquisition, a tender offer, a direct listing, a conventional IPO, or extended private status, and each produces different outcomes for common holders. ElevenLabs has already run a staff tender, which is worth noting because interim liquidity for a name like this often arrives through tender windows. Management has pointed to IPO readiness in two to three years, but readiness is not a date, so underwrite a multi-year hold. Our exit strategy guide and our look at the IPO market for angel investors both go deeper on timing and exit math. Position sizing matters more than conviction in long-duration private assets, so treat any private AI exposure as one slice of a broader portfolio.

Bottom Line

ElevenLabs is a genuinely strong company: a category-defining product, enterprise traction across the Fortune 500, and a revenue curve that justifies the attention. It is also competing against the largest AI labs in the world, navigating real regulatory risk around synthetic voice, and trading at a private premium that only holds if the growth and the quality edge both endure.

Whether it is a good investment for you depends less on what you think of ElevenLabs and more on how you enter it. In a name where demand outstrips supply, the discipline is to not overpay for the story. A measured position at a defensible price, with the right share class, sized appropriately, and a clear-eyed view on liquidity, can fit a balanced portfolio. An emotional position at any price probably cannot.

This is also the kind of opportunity that is hard to reach as a solo angel. Hustle Fund is an early-stage fund, but Angel Squad members get access to deal flow that spans the full spectrum, from pre-seed all the way through pre-IPO names of this caliber. It is a community of 2,500+ members across 50+ countries who have collectively put $30M+ into 70+ startups, with a strict no-a-holes policy and access to what we think is the top 1% of deals. If you want to evaluate growth-stage secondaries with people who actually read the documents, come check out Angel Squad. The investors who do best in private markets stay allergic to hype, read the fine print, and remember that structure often matters as much as story.

Frequently Asked Questions

Is ElevenLabs publicly traded? No. ElevenLabs is a private company with no ticker symbol and no public listing. Accredited investors can access shares through secondary platforms like Notice, Forge Global, Hiive, and EquityZen, through pre-IPO funds, or through angel investing communities that occasionally surface SPV access to growth-stage AI deals.

What is ElevenLabs' current valuation? ElevenLabs was valued at $11 billion in its early-2026 Series D, led by Sequoia Capital. That was roughly 3x its $3.3 billion valuation a year earlier, with a $6.6 billion staff tender offer in between. If you see a far lower "valuation" on a secondary summary screen, that is usually a share-count artifact rather than the real round price.

Who is the CEO of ElevenLabs? ElevenLabs was co-founded in 2022 and is led by CEO Mati Staniszewski. The company is headquartered in New York.

How much revenue does ElevenLabs generate? ElevenLabs crossed roughly $500 million in ARR by April 2026, up from about $330 million at the end of 2025 and around $120 million in 2024. Revenue comes from usage-based subscriptions across self-serve and enterprise customers, with enterprise voice agents driving most of the recent growth.

Is ElevenLabs profitable? ElevenLabs has not disclosed profitability, margins, or EBITDA. The business is compute- and research-intensive and is expanding internationally, so the investment case rests on continued growth and a durable quality advantage, not a disclosed earnings floor.

How can accredited investors buy ElevenLabs stock? Through secondary platforms (Notice, Forge Global, Hiive, EquityZen), pre-IPO funds, and angel investing communities that source SPV access to growth-stage deals. Each path has different minimums, fees, compliance steps, and information rights. Verify the share class, whether you are buying shares or a forward purchase contract, how many SPV layers sit in between, and the transfer and ROFR terms before transacting.